Harmony Biosciences : HRMY Q4 FY 22 Earnings Presentation FINAL

Q4 & Full Year 2022

Financial and Business Update

February 21, 2023

Forward Looking Statements

This presentation includes forward‐looking statements within the meaning of the Private Securities Reform Act of 1995. All statements other than statements of historical facts contained in these materials or elsewhere, including statements regarding Harmony Biosciences Holdings, Inc.'s (the "Company") future financial position, business strategy and plans and objectives of management for future operations, should be considered forward-looking statements. Forward-looking

statements use words like "believes," "plans," "expects," "intends," "will," "would," "anticipates," "estimates," and similar words or expressions in discussions of the Company's future operations, financial performance or the Company's strategies. These statements are based on current expectations or objectives that are inherently uncertain, especially in light of the Company's limited operating history. These and other important factors discussed under the caption "Risk Factors" in the Company's Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (the "SEC") on February 21, 2023 and its other filings with the SEC could cause actual results to differ materially and adversely from those indicated by the forward-looking statements made in this presentation. While the Company may elect to update such forward-looking statements at some point in the future, it disclaims any obligation to do so, even if subsequent events cause its views to change.

This presentation includes information related to market opportunity as well as cost and other estimates obtained from internal analyses and external sources. The internal analyses are based upon management's understanding of market and industry conditions and have not been verified by independent sources. Similarly, the externally sourced information has been obtained from sources the Company believes to be reliable, but the accuracy and completeness of such information cannot be assured. Neither the Company, nor any of its respective officers, directors, managers, employees, agents, or representatives, (i) make any representations or warranties, express or implied, with respect to any of the information contained herein, including the accuracy or completeness of this presentation or any other written or oral information made available to any interested party or its advisor (and any liability therefore is expressly disclaimed), (ii) have any liability from the use of the information, including with respect to any forward-looking statements, or (iii) undertake to update any of the information contained herein or provide additional information as a result of new information or future events or developments.

2

Our Three-Pillar Growth Strategy

Optimize WAKIX®		Expand Clinical Utility of		Acquire
Performance		Pitolisant		New Assets

DESIGNED TO SUPPORT LONG TERM SUSTAINABLE GROWTH

3

WAKIX® Net Revenue Performance

CONFIDENT IN WAKIX BECOMING A POTENTIAL >$1B+ FRANCHISE VIA NARCOLEPSY AND ADDITIONAL INDICATIONS

WAKIX QUARTERLY NET REVENUE ($M)

										41%
												$128.4
											$117.2
										$107.0
							$80.7	$91.2	$85.3
						$73.8
				$56.3	$59.7
		$38.0	$45.6
	$19.8
$6.0
Q4 19	Q1 20	Q2 20	Q3 20	Q4 20	Q1 21	Q2 21	Q3 21	Q4 21	Q1 22	Q2 22	Q3 22	Q4 22

WAKIX ANNUAL NET REVENUE ($M)

	43%
	$437.9
$305.4
FY 2021	FY 2022
	4

Driving Growth Through Strong Commercialization of WAKIX®

Q4 2022 Performance

>80%~4,900

U.S. Covered Lives With	Average # of
Formulary Access
Patients on WAKIX

Continued Growth	~85%
in Depth & Breadth of Prescriber Base	In-Person Access to HCPs

5